Financial Data and Key Metrics Changes - Total revenue for 2025 was $28.1 million, a slight decrease from $28.3 million in 2024, indicating stability despite operational challenges [12][14] - Fourth quarter revenue decreased by 14.8% to $7.7 million compared to $9.1 million in the prior period, primarily due to the expiration of contracts and lower treatment volumes [11][12] - Gross margin for the fourth quarter was approximately $906 thousand or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [12] - Net loss attributable to the company improved to $631 thousand or $0.09 per diluted share, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [12] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million, reflecting the company's strategic transition [13] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [13] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [13] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Mexico, and leadership positions in Ecuador and Peru [9] - The company is expanding its footprint in international markets, including the development of a new center in Guadalajara, Mexico, expected to begin operations in 2026 [9] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, which are key to its long-term strategy and operational foundation [4] - A transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a more stable platform for growth [4][6] - Future growth initiatives include increasing treatment volumes, driving operational efficiencies, and expanding through disciplined development [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges such as physician turnover and reimbursement dynamics but emphasized decisive actions taken to address these issues [5][10] - The company is optimistic about 2026, citing a strong foundation for future growth supported by partnerships and expanded clinical capacity [10][47] - Management is engaged with lending partners to enhance capital structure and support long-term growth initiatives [6][15] Other Important Information - The company ended the year with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [14][15] - Total debt at year-end was approximately $17.3 million, with discussions ongoing regarding amendments to the credit facility [15] Q&A Session Summary Question: Will the company be able to offset temporary revenue distortions by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [18][19] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, with staffing initiatives starting several months in advance [20][21] Question: Why were the expired contracts not disclosed earlier? - Management clarified that the expiration of contracts was mentioned in past calls, and the health systems opted to update equipment independently [25][29] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, citing foundational issues that have been addressed [30][32] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that a stock buyback program has not been a priority and is unlikely to change under current lender conditions [41]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $28.1 million, a slight decrease from $28.3 million in 2024 [12][14] - Fourth quarter revenue decreased by 14.8% to $7.7 million compared to $9.1 million in the prior period, primarily due to the expiration of three Gamma Knife contracts and lower proton beam radiation therapy volumes [11] - Gross margin for Q4 was approximately $906,000 or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [12] - Net loss attributable to the company improved to $631,000 or $0.09 per diluted share in Q4, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [12] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million [13] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [13] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [13] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Peru, and leadership positions in Ecuador and Peru [9] - The company is developing a new center in Guadalajara, Mexico, expected to begin operations in 2026, which represents significant future opportunity [9] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, expanding clinical capabilities, and enhancing patient access to advanced cancer care [4] - A strategic transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a stable platform for long-term growth [4][10] - Future priorities include increasing treatment volumes, driving operational efficiencies, and expanding the footprint through disciplined development [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in 2025, including physician turnover and reimbursement dynamics, but emphasizes decisive actions taken to address these issues [5][10] - The company is optimistic about 2026, supported by strengthened partnerships and a clear development pipeline [10][48] - Management remains focused on delivering high-quality cancer care and creating long-term value for shareholders [48] Other Important Information - The company ended the year with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [14][15] - Total debt at year-end was approximately $17.3 million, with ongoing discussions with lenders regarding amendments and potential restructuring of credit facilities [15] Q&A Session Summary Question: Will the company be able to offset equipment upgrade impacts by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [18][19] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028, with staffing starting several months in advance [20][21] Question: Why were the expired contracts not disclosed earlier? - Management explained that the expiration of contracts was mentioned in past calls, and the health systems opted to update equipment themselves [25][28] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, emphasizing that foundational issues have been addressed [30][32] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that the company has not been interested in a stock buyback program and that current lender conditions make it unlikely to change [40][42]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 decreased by 14.8% to $7.7 million compared to $9.1 million in Q4 2024, primarily due to the expiration of Gamma Knife contracts and lower proton beam radiation therapy volumes [12] - For the full year 2025, total revenue was $28.1 million, slightly down from $28.3 million in 2024 [13] - Gross margin for Q4 2025 was approximately $906 thousand or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [13] - Net loss attributable to the company improved to $631 thousand or $0.09 per diluted share, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [13] - Adjusted EBITDA for the full year was $5.5 million, down from $8.9 million in 2024 [16] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million [14] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [14] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [14] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Mexico, and leadership positions in Ecuador and Peru [10] - The company is developing a new center in Guadalajara, Mexico, expected to begin operations in 2026, which represents significant future opportunity [10] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, expanding clinical capabilities, and enhancing patient access to advanced cancer care [4] - A transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a stable platform for long-term growth [4] - Future priorities include increasing treatment volumes, driving operational efficiencies, and expanding the footprint through disciplined development [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in 2025, including physician turnover and reimbursement dynamics, but emphasized decisive actions taken to address these issues [5] - The company is optimistic about 2026, citing a strong foundation for future growth supported by partnerships and expanded clinical capacity [11] - Ongoing discussions with lenders regarding capital structure enhancements are constructive, aiming to support long-term growth initiatives [6] Other Important Information - The company ended 2025 with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [16] - Total debt at year-end was approximately $17.3 million, with certain financial covenants not met due to lower profitability and higher operating costs [17] Q&A Session Summary Question: Will the company be able to offset revenue declines from expired contracts by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [21] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028, with staffing initiatives starting several months in advance [22] Question: Why were the expired contracts not disclosed earlier? - Management explained that the expiration of contracts was previously mentioned, and the health systems opted to update their equipment independently [28][31] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, emphasizing that foundational issues have been addressed [35] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that the company has not been interested in a stock buyback program and that current lender conditions make it unlikely to change this stance [44]

Core Insights - American Shared Hospital Services reported a year of transition and operational expansion in 2025, integrating new radiation therapy centers and enhancing treatment capabilities [4] - The company announced a seven-year extension of its Proton Therapy lease agreement with Orlando Health, emphasizing long-term partnerships in cancer care [4] - The focus for 2026 includes optimizing operations, expanding patient access, and pursuing strategic growth opportunities [4] Financial Highlights - For the full year 2025, total revenue decreased by 0.9% to $28.1 million compared to $28.3 million in 2024 [16] - The net loss for 2025 was $1.6 million or $0.23 per share, a decline from a net income of $2.2 million or $0.33 per share in 2024 [19] - Adjusted EBITDA for 2025 was $5.5 million, down from $8.9 million in 2024 [20] Segment Performance Direct Patient Care Services - Revenue from direct patient care services increased by 23.7% year-over-year to $15.5 million, driven by new centers in Rhode Island and Puebla, Mexico [16] - LINAC revenue reached $11.5 million, up 35.4% year-over-year, while Gamma Knife revenue was $9.2 million, down 5.5% [5][16] - The direct patient care services segment represented 63% of total sales in Q4 2025, compared to 52% in the prior year [13] Medical Equipment Leasing - Leasing revenue decreased by 33.9% to $2.9 million in Q4 2025, primarily due to the expiration of three Gamma Knife agreements and lower Proton Beam Radiation Therapy volumes [14][17] - Same-center Gamma Knife procedures increased by 11.3%, supported by equipment upgrades [10] Operational Developments - The company completed the upgrade of its Gamma Knife unit in Lima, Peru, enhancing treatment capabilities [6] - The Rhode Island centers and the Puebla center contributed to increased patient volumes and revenue growth [7] Balance Sheet Highlights - As of December 31, 2025, cash and cash equivalents were $3.7 million, down from $11.3 million a year earlier, reflecting capital investments [21] - Total current portion of long-term debt was approximately $17.3 million, with ongoing discussions with lenders regarding financial covenants [22] - Shareholders' equity was $24.0 million or $3.66 per share, compared to $25.2 million or $3.92 per share at the end of 2024 [23]

Core Viewpoint - American Shared Hospital Services (AMS) is set to hold a conference call on March 31, 2026, to discuss its fourth quarter and full year 2025 financial results, with a press release to be issued before market opening on the same day [1][2]. Group 1: Conference Call Details - The conference call will take place at 12:00 PM ET on March 31, 2026 [1]. - Domestic callers can join by dialing 1-844-413-3972, while international callers can dial 1-412-317-5776 [3]. - A simultaneous webcast will be available on the company's website, and a replay of the call will be accessible until April 7, 2026 [3]. Group 2: Company Overview - AMS is a leading provider of turnkey solutions for cancer treatment centers, health systems, and cancer networks across North and South America [4]. - The company collaborates with partners to enhance cancer service lines and deliver integrated cancer care locally [4]. - AMS shares capital investment costs and profitability with health system partners based on ownership interests [4].

Elekta Update Summary Company Overview - **Company**: Elekta (OTCPK:EKTA.Y) - **Date of Update**: January 30, 2026 - **Key Speakers**: Peter Nyquist (Head of Investor Relations), Jacob (CEO), Christopher Busch (Chief Product and Technology Officer), Anming Gong (Head of Region China), Ardie Ermers (Head of North America) Core Industry Insights - **Industry**: Radiation Therapy - **Market Growth**: The radiation therapy market has historically grown at a CAGR above the medtech average, with a current market growth rate of 6% while Elekta's growth is at 3% [11][12] - **Market Dynamics**: The market is not a zero-sum game; innovation in radiation therapy is creating opportunities for market expansion and substitution of traditional treatments like surgery [9][10] Strategic Priorities (Must-Win Battles) 1. **Simplify, Empower, and Speed**: A new operating model aimed at increasing organizational velocity and decision-making speed, with expected annual savings of SEK 500 million [2][23] 2. **Focus Innovation**: Emphasis on developing a strong product portfolio that meets customer needs, particularly through software innovations and workflow efficiencies [25][30] 3. **Win in the U.S. and Expand in China**: Strategies to enhance market share in the U.S. and capitalize on growth opportunities in China [2][39] 4. **Continuous Cost of Goods Sold (COGS) Reduction**: Aiming to improve gross margins, which have declined to around 37-38% from pre-COVID levels in the mid-forties [12][59] Financial Performance and Challenges - **Gross Margin**: Decline attributed to higher costs of materials and services, with a focus on reducing these costs through better sourcing and manufacturing practices [58][59] - **Market Share**: Elekta has been losing market share over the past decade, particularly in the U.S., where only about 20% of revenue is generated [16][48] - **R&D Investment**: Elekta invests approximately 12% of revenue in R&D, which is essential for maintaining competitive solutions [13][15] Regional Insights China - **Market Leadership**: Elekta is a market leader in China for LINAC, Brachytherapy, and Oncology Information Systems, with a focus on localization and partnerships to enhance competitiveness [41][42] - **Market Recovery**: Following a significant decline in the market, recovery is expected starting May 2025, driven by government initiatives to establish oncology departments [44][45] United States - **Underperformance**: Elekta has underperformed in the U.S. market, particularly in the CT Linac space, but has received clearance for the Evo platform, which is expected to drive market share gains [49][50] - **Aging Install Base**: The average age of LINACs in the U.S. is 12-14 years, presenting a significant replacement opportunity for Elekta [51] Innovation and Product Development - **Focus on Software**: Increasing emphasis on software-driven solutions and workflow integration to enhance treatment efficiency and patient outcomes [28][37] - **Agile Innovation**: Transitioning from long-term development cycles to faster, incremental innovation cycles to better meet customer needs [35][36] Conclusion and Future Outlook - **Execution Focus**: Elekta is committed to executing its strategic priorities and expects to establish a new operating model by the end of Q4 [63] - **Capital Markets Day**: A detailed financial outlook and new targets will be presented at the Capital Markets Day scheduled for June 17 [2][65]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 increased by 2.5% to $7.2 million compared to $7 million in Q3 2024 [16] - Year-to-date revenues increased by 5.6% to $20.4 million compared to $19.3 million in the first nine months of 2024 [18] - Adjusted EBITDA for Q3 2025 was $1.9 million, a 42% increase from $1.3 million in Q3 2024 [9][18] - Gross margins improved to 22.1% in Q3 2025, with a 60% year-over-year increase to $1.6 million [18] Business Line Data and Key Metrics Changes - Revenue from direct patient services increased by 9.4% to $4 million in Q3 2025, driven by increased procedures at the new facility in Puebla, Mexico [16] - Gamma Knife revenue increased by 16% year-over-year to $2.1 million in Q3 2025, with the number of procedures rising to 231 from 218 in Q3 2024 [17] - Revenue from the medical equipment leasing segment decreased to $3.1 million from $3.3 million in Q3 2024 due to lower proton beam radiation therapy volumes [16] Market Data and Key Metrics Changes - The new radiation therapy treatment center in Puebla, Mexico showed a remarkable 263% annual revenue growth [8] - The company expects continued growth in treatment volumes, particularly in Rhode Island, as new radiation oncologists engage with the healthcare community [10] Company Strategy and Development Direction - The company is transitioning from a medical equipment leasing focus to a more patient-centric service model, which is expected to enhance long-term shareholder value [4][5] - The acquisition of three Rhode Island cancer treatment centers and the new center in Puebla, Mexico are seen as significant growth opportunities [10] - Plans to construct a fourth radiation therapy center in Bristol, Rhode Island, and the first proton beam radiation therapy center in the state are underway, representing major growth opportunities [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term growth strategy and the ability to weather short-term fluctuations [13] - The management team is focused on operational efficiencies and building momentum as growth strategies take hold [35] Other Important Information - The company entered Q3 2025 with cash and cash equivalents of $5.1 million, down from $11 million at the end of 2024, reflecting capital expenditures for expansion [22] - Shareholders' equity was $24.6 million, or $3.78 per outstanding share, compared to $25.2 million, or $3.92 per share at the end of 2024 [23] Q&A Session Summary Question: Concerns about shareholder value and investor outreach - A shareholder expressed concerns about the company's market cap relative to its EBITDA and suggested increased investor outreach [26] - Management acknowledged the need for more outreach and recognized the importance of communicating the company's progress to shareholders [28] Question: Disconnect between market valuation and company performance - Another investor questioned why the stock is trading at a 52-week low despite positive results and growth prospects [30] - Management attributed this to thin trading and lack of exposure, agreeing that increased outreach is necessary [32]

Core Points - American Shared Hospital Services (AMS) will hold a conference call on November 13, 2025, at 1:00 PM ET to discuss its third quarter 2025 financial results [2] - The financial results press release will be issued before the market opens on the same day [3] Teleconference and Webcast Information - Domestic callers can dial 1-844-413-3972 and international callers can dial 1-412-317-5776 to join the call [4] - A simultaneous webcast will be available on the company's website [4] - A replay of the call will be accessible until November 20, 2025 [4] Company Overview - AMS is a leading provider of turnkey solutions for cancer treatment centers in North and South America [5] - The company collaborates with health systems to develop cancer service lines and provide integrated care [5] - AMS shares capital investment costs and profitability with its health system partners based on ownership interests [5]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 16% sequentially to $7.1 million compared to $6.1 million in Q1 2025 [17] - Adjusted EBITDA for Q2 2025 was $1.7 million, up from $949,000 in Q1 2025 [11][21] - Net loss for Q2 2025 was $280,000, an improvement from a net loss of $625,000 in Q1 2025 [21] Business Line Data and Key Metrics Changes - Revenue from the Direct Patient Services segment was $3.5 million in Q2 2025, a 12% increase from $3.1 million in Q2 2024 [18] - Revenue from the equipment leasing segment decreased to $3.6 million from $3.9 million in Q2 2024 [18] - Gamma Knife revenue increased by 25% from Q1 2025 to $2.6 million in Q2 2025, but was down about 5% compared to Q2 2024 [19] Market Data and Key Metrics Changes - The company continues to see growth in international markets, particularly with the Gamma Knife centers in Peru and Ecuador, and the new center in Puebla, Mexico [13] - The acquisition of Rhode Island cancer treatment centers has significantly contributed to revenue growth [10][12] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model, which is expected to drive long-term growth [6][7] - Plans to expand operations include building a fourth radiation therapy treatment center in Bristol, Rhode Island, and a proton beam radiation therapy center [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory, emphasizing the importance of focusing on overall growth opportunities [8][16] - The company anticipates fluctuations in treatment volumes but remains optimistic about steady growth in the overall business [11][16] Other Important Information - The company ended Q2 2025 with cash and cash equivalents of $11.3 million, consistent with the end of 2024 [25] - Shareholders' equity was $24.5 million, down from $25.2 million at the end of 2024 [26] Q&A Session Summary Question: Are there any pre-opening activities for the new locations in Rhode Island? - Management confirmed the addition of three full-time radiation oncologists to support the new centers, which will enhance service delivery [30][31] Question: Will these activities benefit the new centers? - Management affirmed that there are economies of scale with the expansion within the Rhode Island marketplace [33]

Core Viewpoint - American Shared Hospital Services reported a 16% sequential increase in total revenue for Q2 2025, driven by growth in treatment volumes and expansion of services [2][5]. Financial Performance - Q2 2025 revenue reached $7,071,000, a 0.2% increase compared to Q2 2024, attributed to expanded radiation therapy services [6]. - Revenue from direct patient services was $3,500,000, an 11% increase year-over-year, primarily due to acquisitions in Rhode Island and the new facility in Puebla, Mexico [6]. - The medical equipment leasing segment saw an 8% decrease in revenue to $3,571,000, impacted by lower Gamma Knife volumes and the expiration of customer contracts [7]. - Proton beam radiation therapy revenue decreased to $1,921,000 from $2,420,000 in the prior year, reflecting cyclical fluctuations [7]. Treatment Volume and Revenue Breakdown - Radiation therapy revenue for Q2 2025 was $2,541,000, up from $1,892,000 in Q2 2024, driven by the Rhode Island centers and Puebla operations [8]. - Gamma Knife revenue increased by 25% sequentially but decreased by 5% compared to Q2 2024 [5]. - LINAC revenue grew by 7% sequentially and 34% year-over-year [5]. - Proton beam radiation therapy revenue increased by 17% sequentially but decreased by 21% compared to Q2 2024 [5]. Profitability and Loss - The company reported a net loss of $280,000 or $0.04 per share for Q2 2025, compared to a net income of $3,602,000 or $0.55 per diluted share in Q2 2024 [9]. - Adjusted EBITDA for Q2 2025 was $1,701,000, down from $2,010,000 in Q2 2024 [9]. Long-term Growth Strategy - The CEO emphasized a focus on expanding the business model and operational enhancements, with expectations for growth from new installations in Mexico and recent approvals for new treatment centers in Rhode Island [4]. - The company has experienced four consecutive years of revenue growth and three years of sustained profitability, with ongoing strategic acquisitions to bolster growth potential [4]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents totaled $11,331,000, slightly up from $11,275,000 at the end of 2024 [14]. - Shareholders' equity was $24,481,000 or $3.78 per share, down from $25,183,000 or $3.92 per share at the end of 2024 [14].